Document_And_Entity_Informatio
Document And Entity Information (USD $) | 12 Months Ended | ||
Dec. 31, 2013 | Mar. 14, 2014 | Jun. 30, 2013 | |
Document Information [Line Items] | ' | ' | ' |
Document Type | '10-K | ' | ' |
Amendment Flag | 'false | ' | ' |
Document Period End Date | 31-Dec-13 | ' | ' |
Document Fiscal Year Focus | '2013 | ' | ' |
Document Fiscal Period Focus | 'FY | ' | ' |
Trading Symbol | 'ADHXF | ' | ' |
Entity Common Stock, Shares Outstanding | ' | 29,307,618 | ' |
Entity Registrant Name | 'ADHEREX TECHNOLOGIES INC | ' | ' |
Entity Central Index Key | '0001211583 | ' | ' |
Current Fiscal Year End Date | '--12-31 | ' | ' |
Entity Well-known Seasoned Issuer | 'No | ' | ' |
Entity Voluntary Filers | 'No | ' | ' |
Entity Current Reporting Status | 'Yes | ' | ' |
Entity Filer Category | 'Smaller Reporting Company | ' | ' |
Entity Public Float | ' | ' | $2,802,147 |
Consolidated_Balance_Sheets
Consolidated Balance Sheets (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Current assets | ' | ' |
Cash and cash equivalents | $1,663 | $2,303 |
Prepaid expense | 81 | 56 |
Other current assets | 8 | 6 |
Total assets | 1,752 | 2,365 |
Current liabilities | ' | ' |
Accounts payable | 212 | 259 |
Accrued liabilities | 132 | 423 |
Derivative liabilities | 2,863 | 6,640 |
Total current liabilities | 3,207 | 7,322 |
Total liabilities | 3,207 | 7,322 |
Commitments and contingencies (Note 8) | ' | ' |
Stockholders' (deficit) equity | ' | ' |
Common stock, no par value; unlimited shares authorized; (2013 - 29,158, 2012 - 25,158 shares issued and outstanding) | 66,790 | 65,952 |
Additional paid-in capital | 39,210 | 38,391 |
Deficit accumulated during development stage | -108,698 | -110,543 |
Accumulated other comprehensive income | 1,243 | 1,243 |
Total stockholders' (deficit) equity | -1,455 | -4,957 |
Total liabilities and stockholders' (deficit) equity | $1,752 | $2,365 |
Consolidated_Balance_Sheets_Pa
Consolidated Balance Sheets (Parenthetical) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, except Per Share data, unless otherwise specified | ||
Common stock, no par value | $0 | $0 |
Common stock, shares issued | 29,158 | 25,158 |
Common stock, shares outstanding | 29,158 | 25,158 |
Consolidated_Statements_of_Ope
Consolidated Statements of Operations (USD $) | 12 Months Ended | 208 Months Ended | |
In Thousands, except Per Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 |
Revenue | $0 | $0 | $0 |
Operating expenses: | ' | ' | ' |
Research and development | 597 | 2,075 | 69,765 |
Impairment of capital assets | 0 | 0 | 386 |
Gain on deferred lease inducements | 0 | 0 | -497 |
Acquired in-process research and development | 0 | 0 | 13,094 |
General and administration | 1,334 | 1,545 | 33,428 |
Loss from operations | -1,931 | -3,620 | -116,176 |
Other income (expense): | ' | ' | ' |
Gain/(loss) on derivative warrants | 3,777 | -1,563 | 7,034 |
Settlement of Cadherin Biomedical Inc. litigation | 0 | 0 | -1,283 |
Interest expense | 0 | 0 | -19 |
Other (expense)/income | -3 | -5 | 256 |
Interest income | 2 | 25 | 2,899 |
Total other income/(expense) | 3,776 | -1,543 | 8,887 |
Net income/(loss) and total comprehensive income/(loss) | $1,845 | ($5,163) | ($107,289) |
Earnings/(loss) per share of common stock, basic (In dollars per share) | $0.06 | ($0.21) | ' |
Earnings/(loss) per share of common stock, diluted (In dollars per share) | $0.06 | ($0.21) | ' |
Weighted-average number of shares of common stock outstanding, basic (In shares) | 29,158 | 25,158 | ' |
Weighted-average number of shares of common stock outstanding, diluted (In shares) | 31,714 | 25,158 | ' |
Consolidated_Statements_of_Cas
Consolidated Statements of Cash Flows (USD $) | 12 Months Ended | 208 Months Ended | |
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 |
Operating activities: | ' | ' | ' |
Net income/(loss) | $1,845 | ($5,163) | ($107,289) |
Adjustments for non-cash items: | ' | ' | ' |
(Gain)/Loss on derivative warrants | -3,777 | 1,563 | -7,034 |
Depreciation and amortization | 0 | 0 | 1,404 |
Non-cash Cadherin Biomedical Inc. litigation expense | 0 | 0 | 1,187 |
Unrealized foreign exchange loss | ' | 0 | 36 |
Loss on impairment of capital assets | 0 | 0 | 386 |
Amortization of and gain on lease inducements | 0 | 0 | -412 |
Non-cash severance expense | 0 | 0 | 168 |
Stock options issued to consultants | 25 | 152 | 1,073 |
Stock options issued to employees | 62 | 174 | 10,331 |
Acquired in-process research and development | 0 | 0 | 13,094 |
Changes in non-cash working capital | -365 | 280 | -191 |
Net cash used in operating activities | -2,210 | -2,994 | -87,247 |
Investing activities: | ' | ' | ' |
Purchase of capital assets | 0 | 0 | -1,440 |
Disposal of capital assets | 0 | 0 | 115 |
Proceeds from sale of assets | 0 | 0 | 24 |
Release of restricted cash | 0 | 0 | 190 |
Restricted cash | 0 | 0 | -209 |
Purchase of short-term investments | 0 | 0 | -22,148 |
Redemption of short-term investments | 0 | 0 | 22,791 |
Investment in Cadherin Biomedical Inc. | 0 | 0 | -166 |
Acquired intellectual property rights | 0 | 0 | -640 |
Net cash used in investing activities | 0 | 0 | -1,483 |
Financing activities: | ' | ' | ' |
Conversion of long-term debt to equity | 0 | 0 | 68 |
Long-term debt repayments | 0 | 0 | -65 |
Capital lease repayments | 0 | 0 | -8 |
Issuance of common stock | 1,570 | 0 | 88,013 |
Registration expense | 0 | 0 | -465 |
Financing expenses | 0 | 0 | -544 |
Proceeds from convertible note | 0 | 0 | 3,017 |
Other liability repayments | 0 | 0 | -87 |
Security deposits received | 0 | 0 | 35 |
Proceeds from exercise of stock options | 0 | 0 | 51 |
Net cash provided from financing activities | 1,570 | 0 | 90,015 |
Effect of exchange rate changes on cash and cash equivalents | 0 | 0 | 378 |
Net change in cash and cash equivalents | -640 | -2,994 | 1,663 |
Cash and cash equivalents - Beginning of year | 2,303 | 5,297 | 0 |
Cash and cash equivalents - End of year | $1,663 | $2,303 | $1,663 |
Consolidated_Statement_of_Stoc
Consolidated Statement of Stockholders' Equity (Deficiency) (USD $) | Total | Warrant [Member] | Settlement of Advances [Member] | Initial Public Offering [Member] | Series A Special Warrants [Member] | Rights [Member] | Oxiquant [Member] | Consultants [Member] | Financing Warrant [Member] | Financing Warrant [Member] | Convertible Notes Payable [Member] | Convertible Notes Payable [Member] | Nonredeemable Preferred Stock [Member] | Private Placement [Member] | Private Placement [Member] | Private Placement [Member] | Private Placement [Member] | Private Placement [Member] | Employees [Member] | Cadherin Biomedical Inc. [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Common Stock [Member] | Non-redeemable Preferred Stock of Subsidiary [Member] | Non-redeemable Preferred Stock of Subsidiary [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Additional Paid-in Capital [Member] | Accumulated Other Comprehensive Income [Member] | Deficit Accumulated During Development Stage [Member] | Deficit Accumulated During Development Stage [Member] | Deficit Accumulated During Development Stage [Member] |
In Thousands | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | February 2007 Financing [Member] | June 2004 Convertible Notes [Member] | December 2004 Convertible Notes [Member] | USD ($) | December 2004 Placement [Member] | May 2004 Placement [Member] | July 2005 Placement [Member] | May 2006 Placement [Member] | USD ($) | USD ($) | USD ($) | Warrant [Member] | Settlement of Advances [Member] | Initial Public Offering [Member] | Series A Special Warrants [Member] | Rights [Member] | Oxiquant [Member] | Financing Warrant [Member] | Financing Warrant [Member] | Convertible Notes Payable [Member] | Convertible Notes Payable [Member] | Private Placement [Member] | Private Placement [Member] | Private Placement [Member] | Private Placement [Member] | Cadherin Biomedical Inc. [Member] | USD ($) | Nonredeemable Preferred Stock [Member] | USD ($) | Warrant [Member] | Series A Special Warrants [Member] | Rights [Member] | Oxiquant [Member] | Consultants [Member] | Financing Warrant [Member] | Financing Warrant [Member] | Convertible Notes Payable [Member] | Convertible Notes Payable [Member] | Private Placement [Member] | Private Placement [Member] | Private Placement [Member] | Private Placement [Member] | Employees [Member] | USD ($) | USD ($) | Initial Public Offering [Member] | Rights [Member] | |
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | February 2007 Financing [Member] | April 2010 Financing [Member] | June 2004 Convertible Notes [Member] | December 2004 Convertible Notes [Member] | December 2004 Placement [Member] | May 2004 Placement [Member] | July 2005 Placement [Member] | May 2006 Placement [Member] | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | February 2007 Financing [Member] | June 2004 Convertible Notes [Member] | December 2004 Convertible Notes [Member] | December 2004 Placement [Member] | May 2004 Placement [Member] | July 2005 Placement [Member] | May 2006 Placement [Member] | USD ($) | USD ($) | USD ($) | |||||||||||||||||||
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | ||||||||||||||||||||||||||||||||||||||||||||
Beginning Balance at Sep. 02, 1996 | $0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0 | ' | $0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0 | $0 | ' | ' |
Beginning Balance (in shares) at Sep. 02, 1996 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 89 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net (loss) income | -37 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -37 | ' | ' |
Ending Balance at Jun. 30, 1997 | -37 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -37 | ' | ' |
Ending Balance (in shares) at Jun. 30, 1997 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 89 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net (loss) income | -398 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -398 | ' | ' |
Ending Balance at Jun. 30, 1998 | -435 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -435 | ' | ' |
Beginning Balance (in shares) at Jun. 30, 1998 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 89 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exchange of Adherex Inc. shares for Adherex Technologies Inc. shares (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -89 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 239 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock | 1,615 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,615 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cumulative translation adjustment | 20 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20 | ' | ' | ' |
Net (loss) income | -958 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -958 | ' | ' |
Ending Balance at Jun. 30, 1999 | 242 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,615 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20 | -1,393 | ' | ' |
Ending Balance (in shares) at Jun. 30, 1999 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 239 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of warrants | ' | 255 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 255 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 16 | ' | 16 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock | 793 | ' | 175 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 793 | ' | 175 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of equity rights | 171 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 171 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cancellation of common stock (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -7 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cumulative translation adjustment | 16 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 16 | ' | ' | ' |
Net (loss) income | -1,605 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -1,605 | ' | ' |
Ending Balance at Jun. 30, 2000 | 47 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,583 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 426 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 36 | -2,998 | ' | ' |
Ending Balance (in shares) at Jun. 30, 2000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 264 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of warrants | ' | 1,722 | ' | ' | 4,335 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,722 | 4,335 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Other | 341 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 341 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 74 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock | ' | ' | ' | 5,689 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,727 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -38 | ' |
Conversion of convertible securities (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 30 | ' | ' | 69 | 4 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Conversion of convertible securities | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,977 | ' | ' | 4,335 | 171 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -1,977 | -4,335 | -171 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cumulative translation adjustment | 182 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 182 | ' | ' | ' |
Net (loss) income | -2,524 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -2,524 | ' | ' |
Ending Balance at Jun. 30, 2001 | 9,792 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,134 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 218 | -5,560 | ' | ' |
Ending Balance (in shares) at Jun. 30, 2001 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 446 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cumulative translation adjustment | 11 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 11 | ' | ' | ' |
Net (loss) income | -3,732 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -3,732 | ' | ' |
Ending Balance at Jun. 30, 2002 | 6,071 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,134 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 229 | -9,292 | ' | ' |
Beginning Balance (in shares) at Jun. 30, 2002 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 446 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of warrants | ' | 53 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 53 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options issued | ' | ' | ' | ' | ' | ' | ' | 4 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Equity component of convertible notes | 1,058 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,058 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 446 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock | ' | ' | ' | ' | ' | ' | 11,620 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 11,077 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 543 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of stock options (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of stock options | 4 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Distribution to shareholders | -158 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -158 | ' | ' |
Stated capital reduction | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -9,489 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,489 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cumulative translation adjustment | -159 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -159 | ' | ' | ' |
Net (loss) income | -17,795 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -17,795 | ' | ' |
Ending Balance at Jun. 30, 2003 | 698 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 16,726 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 11,147 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 70 | -27,245 | ' | ' |
Ending Balance (in shares) at Jun. 30, 2003 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 893 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Repricing of warrants related to financing | 18 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 18 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of warrants | ' | ' | ' | ' | ' | ' | ' | ' | 54 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 54 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options issued | ' | ' | ' | ' | ' | ' | ' | 148 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 148 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Equity component of convertible notes | 1,983 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,983 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 640 | 259 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,045 | ' | 13,830 | 8,474 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,053 | 6,356 | ' | ' | ' | ' | 1,045 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,777 | 2,118 | ' | ' | ' | ' | ' | ' | ' |
Conversion of convertible securities (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 96 | 60 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Conversion of convertible securities | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,123 | 171 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,216 | 569 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -93 | -398 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of stock options (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of stock options | 23 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 23 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amalgamation of 2037357 Ontario Inc. | -22 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 660 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -1,045 | ' | 363 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amalgamation of 2037357 Ontario Inc., (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 44 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cumulative translation adjustment | -219 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -219 | ' | ' | ' |
Net (loss) income | -6,872 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -6,872 | ' | ' |
Ending Balance at Jun. 30, 2004 | 20,454 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 33,603 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 21,117 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -149 | -34,117 | ' | ' |
Ending Balance (in shares) at Jun. 30, 2004 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,993 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cost related to SEC registration | -493 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -493 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options issued | ' | ' | ' | ' | ' | ' | ' | 39 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 604 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 39 | ' | ' | ' | ' | ' | ' | ' | ' | 604 | ' | ' | ' | ' |
Stock Issued for Acquisitions (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 37 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock Issued for Acquisitions | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,252 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,252 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Cumulative translation adjustment | 1,392 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,392 | ' | ' | ' |
Net (loss) income | -6,594 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -6,594 | ' | ' |
Ending Balance at Dec. 31, 2004 | 16,654 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 34,362 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 21,760 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,243 | -40,711 | ' | ' |
Ending Balance (in shares) at Dec. 31, 2004 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,030 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Financing costs | -141 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -141 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options issued | ' | ' | ' | ' | ' | ' | ' | 276 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 276 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 337 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,134 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7,060 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,074 | ' | ' | ' | ' | ' | ' |
Exercise of stock options (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of stock options | 25 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 25 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net (loss) income | -13,871 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -13,871 | ' | ' |
Ending Balance at Dec. 31, 2005 | 11,077 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 41,306 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 23,110 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,243 | -54,582 | ' | ' |
Ending Balance (in shares) at Dec. 31, 2005 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,368 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options issued | ' | ' | ' | ' | ' | ' | ' | 100 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 491 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 100 | ' | ' | ' | ' | ' | ' | ' | ' | 491 | ' | ' | ' | ' |
Issuance of stock (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 431 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,040 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,218 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 822 | ' | ' | ' | ' | ' |
Net (loss) income | -16,440 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -16,440 | ' | ' |
Ending Balance at Dec. 31, 2006 | 1,268 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 46,524 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 24,523 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,243 | -71,022 | ' | ' |
Beginning Balance (in shares) at Dec. 31, 2006 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,799 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of warrants (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 116 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Exercise of warrants | 694 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 563 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 131 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options issued | ' | ' | ' | ' | ' | ' | ' | 59 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,263 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 59 | ' | ' | ' | ' | ' | ' | ' | ' | 2,263 | ' | ' | ' | ' |
Issuance of stock (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,209 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | 23,221 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 17,842 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,379 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net (loss) income | -13,357 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -13,357 | ' | ' |
Ending Balance at Dec. 31, 2007 | 14,148 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 64,929 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 32,355 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,243 | -84,379 | ' | ' |
Ending Balance (in shares) at Dec. 31, 2007 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7,124 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options issued | ' | ' | ' | ' | ' | ' | ' | 88 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,417 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 88 | ' | ' | ' | ' | ' | ' | ' | ' | 2,417 | ' | ' | ' | ' |
Net (loss) income | -13,600 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -13,600 | ' | ' |
Ending Balance at Dec. 31, 2008 | 3,053 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 64,929 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 34,860 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,243 | -97,979 | ' | ' |
Ending Balance (in shares) at Dec. 31, 2008 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7,124 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options issued | ' | ' | ' | ' | ' | ' | ' | 10 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 355 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10 | ' | ' | ' | ' | ' | ' | ' | ' | 355 | ' | ' | ' | ' |
Net (loss) income | -3,012 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -3,012 | ' | ' |
Ending Balance at Dec. 31, 2009 | 406 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 64,929 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 35,225 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,243 | -100,991 | ' | ' |
Ending Balance (in shares) at Dec. 31, 2009 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7,124 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options issued | ' | ' | ' | ' | ' | ' | ' | 53 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,439 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 53 | ' | ' | ' | ' | ' | ' | ' | ' | 2,439 | ' | ' | ' | ' |
Issuance of stock (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 13,337 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net (loss) income | -7,823 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -7,823 | ' | ' |
Ending Balance at Dec. 31, 2010 | -4,925 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 64,929 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 37,717 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,243 | -108,814 | ' | ' |
Ending Balance (in shares) at Dec. 31, 2010 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20,461 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options issued | ' | ' | ' | ' | ' | ' | ' | 20 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 129 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20 | ' | ' | ' | ' | ' | ' | ' | ' | 129 | ' | ' | ' | ' |
Issuance of stock (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,697 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock | ' | ' | ' | ' | ' | -28 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,023 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 199 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -1,250 |
Net (loss) income | 4,685 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,685 | ' | ' |
Ending Balance at Dec. 31, 2011 | -119 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 65,952 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 38,065 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,243 | -105,379 | ' | ' |
Ending Balance (in shares) at Dec. 31, 2011 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 25,158 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options issued | ' | ' | ' | ' | ' | ' | ' | 152 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 174 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 152 | ' | ' | ' | ' | ' | ' | ' | ' | 174 | ' | ' | ' | ' |
Net (loss) income | -5,163 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | -5,163 | ' | ' |
Ending Balance at Dec. 31, 2012 | -4,957 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 65,952 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 38,391 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,243 | -110,543 | ' | ' |
Ending Balance (in shares) at Dec. 31, 2012 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 25,158 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stock options issued | ' | ' | ' | ' | ' | ' | ' | 25 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 62 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 25 | ' | ' | ' | ' | ' | ' | ' | ' | 62 | ' | ' | ' | ' |
Issuance of stock (in shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Issuance of stock | ' | ' | ' | ' | ' | 1,570 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 838 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 732 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Net (loss) income | 1,845 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,845 | ' | ' |
Ending Balance at Dec. 31, 2013 | ($1,455) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $66,790 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $39,210 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1,243 | ($108,698) | ' | ' |
Ending Balance (in shares) at Dec. 31, 2013 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 29,158 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Going_Concern
Going Concern | 12 Months Ended |
Dec. 31, 2013 | |
Going Concern [Abstract] | ' |
Going Concern | ' |
1. Going Concern | |
Adherex Technologies Inc. (“Adherex”), a British Columbia corporation together with its wholly owned subsidiaries Oxiquant, Inc. (“Oxiquant”) and Adherex, Inc., both Delaware corporations, and Cadherin Biomedical Inc. (“CBI”), a Canadian corporation, collectively referred to herein as the “Company,” is a development stage biopharmaceutical company with a portfolio of product candidates under development for use in the treatment of cancer. With the exception of Adherex Inc., all subsidiaries are inactive. | |
These consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States (“U.S.”) of America that are applicable to a going concern which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business. | |
The Company is a development stage company and during the year ended December 31, 2013, incurred a loss from operations of $1,931. At December 31, 2013, it had an accumulated deficit of $108,698, and had experienced negative cash flows from operating activities since inception in the amount of $87,247. In addition, it had a deficiency in working capital at December 31, 2013 and the Company's operating losses since inception. | |
These circumstances raise substantial doubt as to the ability of the Company to meet its obligations as they come due and, accordingly, the use of accounting principles applicable to a going concern may not be appropriate. The Company will need to obtain additional funding in the future in order to finance our business strategy, operations and growth through the issuance of equity, debt or collaboration. If we fail to arrange for sufficient capital on a timely basis, we may be required to curtail our business activities until we can obtain adequate financing. | |
These financial statements do not reflect the potentially material adjustments in the carrying values of assets and liabilities, the reported expenses, and the balance sheet classifications used, that would be necessary if the going concern assumption were not appropriate. | |
Significant_Accounting_Policie
Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2013 | |
Significant Accounting Policies [Abstract] | ' |
Significant Accounting Policies | ' |
2. Significant Accounting Policies | |
Basis of presentation | |
The consolidated financial statements include the accounts of Adherex and of all its wholly-owned subsidiaries and all inter-company transactions and balances have been eliminated upon consolidation. | |
On August 10, 2011, the Board of Directors approved a 1-for-18 reverse stock split, or “Share Consolidation”, which became effective on August 25, 2011. The 1-for-18 reverse stock split affected all of the Company’s common shares, stock options and warrants outstanding at the effective date. Consequently, the Company has retroactively adjusted its financial statements for all periods presented to show the shares, stock options and warrants as if they had always been presented on this basis. The number of units and unit prices (including with respect to the units issued in our April 2010 Private Placement and the Rights Offering) have not been adjusted to reflect the Share Consolidation, and the number of warrants outstanding have not been adjusted to reflect the Share Consolidation (in accordance with the terms of the warrants, the number of shares of common stock issuable thereunder were adjusted as a result of the Share Consolidation but not the number of warrants outstanding). | |
Use of estimates | |
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include the valuation of derivative warrant liability and the valuation of stock based compensation. Actual results could differ from those estimates. | |
Cash and Cash Equivalents | |
Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less. | |
The Company places its cash and cash equivalents in investments held by financial institutions in accordance with its investment policy designed to protect the principal investment. At December 31, 2013, the Company had $1,663 in cash accounts (2012- $2,303). Money market investments typically have minimal risk; however, in recent years the financial markets have been volatile resulting in concerns regarding money market investments. The Company has not experienced any loss or write-down of its money market investments. | |
Financial instruments | |
Financial instruments recognized on the balance sheets at December 31, 2013 and December 31, 2012 consist of cash and cash equivalents, accounts payable, accrued liabilities and derivative liabilities, the carrying values of which, with the exception of the derivative liabilities, approximate fair value due to their relatively short time to maturity. The Company does not hold or issue financial instruments for trading. The derivative liabilities are carried at fair value. | |
The Company’s investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Investments, when made, are made in U.S. or Canadian bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper. | |
The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments. As the main purpose of the Company is research and development, the Company has chosen to avoid investments of a trade or speculative nature. | |
Common stock and warrants | |
At December 31, 2007, the Company had warrants outstanding to purchase common stock that were denominated in both U.S. and Canadian dollars, which resulted in the Company having warrants outstanding that were denominated outside the Company’s U.S. dollar functional currency. | |
In November 2007, the Emerging Issues Task Force (“EITF”) of the FASB issued EITF No. 07-5, Issue Summary No.1 “Determining Whether an Instrument (or an Embedded Feature) is Indexed to an Entity's Own Stock” (“EITF 07-5”), codified as ASC 815-40. In June 2008, one of the conclusions reached under EITF 07-05 was a consensus that an equity-linked financial instrument would not be considered indexed to the entity's own stock if the strike price is denominated in a currency other than the issuer's functional currency. The issues brought to the EITF for discussion related to how an entity should determine whether certain instruments or embedded features are indexed to its own stock. This discussion included equity-linked financial instruments where the exercise price is denominated in a currency other than the issuer's functional currency; such as the Company’s outstanding warrants to purchase common stock that were denominated in Canadian dollars. This conclusion reached under EITF 07-05 clarified the accounting treatment for these and certain other financial instruments as it related to FASB Statement No. 133, “Accounting for Derivative Instruments and Hedging Activities” (“SFAS 133”), codified as ASC 815-10. SFAS 133 specifies that a contract that would otherwise meet the definition of a derivative under SFAS 133, issued or held by the reporting entity that is both (a) indexed to its own stock and (b) classified in stockholders' equity in its statement of financial position should not be considered a derivative financial instrument for purposes of applying SFAS 133. As a result, the Company’s outstanding warrants denominated in Canadian dollars were not considered to be indexed to its own stock and should therefore be treated as derivative financial instruments and recorded at their fair value as a liability. The Company issued further Canadian dollar denominated warrants on April 30, 2010 and March 29, 2011 and this resulted in warrants being shown as a liability which is marked to market as at December 31, 2013 and December 31, 2012. At December 31, 2013, the derivative liabilities were valued at $2,863 (2012: $6,640) and the unrealized gain on the value of the underlying securities was $3,777 (2012: loss $1,563) for the year ended December 31, 2013. | |
Revenue recognition | |
At this time, the Company does not have any revenue. | |
Research and development costs and investment tax credits | |
Research costs, including employee compensation, laboratory fees, lab supplies, and research and testing performed under contract by third parties, are expensed as incurred. Development costs, including drug substance costs, clinical study expenses and regulatory expenses are expensed as incurred. | |
Investment tax credits, which are earned as a result of qualifying research and development expenditures, are recognized when the expenditures are made and their realization is reasonably assured. They are applied to reduce related capital costs and research and development expenses in the year recognized. | |
Income taxes | |
The Company accounts for income taxes under the asset and liability method that requires the recognition of deferred tax assets or liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and tax basis of assets and liabilities. The Company provides a valuation allowance to reduce its deferred tax assets when it is more likely than not that such assets will not be realized. | |
The Company accounts for uncertainty in income taxes by following the Financial Accounting Standards Board issued Interpretation No. 48 (‘‘FIN 48’’), codified as ASC 740-10-25, ‘‘Accounting for Uncertainty in Income Taxes – an Interpretation of SFAS No. 109.’’ FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements in accordance with Statement of Financial Accounting Standards No. 109, ‘‘Accounting for Income Taxes.’, codified as ASC 740-10. FIN 48 provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the financial statements. FIN 48 requires the evaluation of tax positions taken or expected to be taken in the course of preparing tax returns to determine whether the tax positions have met a “more-likely-than-not” threshold of being sustained by the applicable tax authority. Tax benefits related to tax positions not deemed to meet the “more-likely-than-not” threshold are not permitted to be recognized in the financial statements. Upon adoption of FIN 48, the Company has elected an accounting policy that continues to classify accrued interest and penalties related to liabilities for income taxes in income tax expense. | |
Foreign currency translation | |
The U.S. dollar is the functional currency for the Company’s consolidated operations. For those entities, all gains and losses from currency translations are included in results of operations. | |
Earnings/(Loss) per share | |
Basic net earnings/(loss) per share is computed by dividing net earnings/(loss) by the weighted average number of shares of common stock outstanding during the year. Diluted net earnings per share is computed using the same method, except the weighted average number shares of common stock outstanding includes convertible debentures, stock options and warrants, if dilutive as determined using the if-converted method and treasury methods. Accordingly, options to purchase 5,319 and warrants to purchase 21,665 shares at December 31, 2013, were not included in earnings per share. These options and warrant were not included in the computation of diluted earnings per share because the exercise prices were greater than the average market price of the common shares at that date, and accordingly, such options would have an antidilutive effect. In 2012 we incurred a net loss and accordingly none of the options or warrants outstanding, 5,498 and 18,385, respectively, were included in loss per share because their effect would be antidilutive. | |
Newly adopted accounting pronouncements | |
In February 2013, the FASB issued ASU 2013-02 to improve the reporting of reclassifications out of accumulated other comprehensive income. The ASU provides amendments to the Comprehensive Income subtopic of the FASB ASC, such that companies must report the effect of significant reclassifications out of accumulated comprehensive income on the respective line items in net income. For other amounts that are not required to be reclassified in their entirety to net income, an entity may cross reference to the relevant note disclosure. The Company was required to adopt this ASU in the first quarter for fiscal 2013. The adoption of this standard did not have a significant impact on the Company’s reporting. | |
Recent accounting pronouncements | |
In July 2013, the FASB issued ASU No. 2013-11, "Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists," an amendment to FASB Accounting Standards Codification, or "ASC" Topic 740, Income Taxes, or "FASB ASC Topic 740." This update clarifies that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed. In situations where a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction or the tax law of the jurisdiction does not require, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. This ASU is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption and retrospective application are permitted. This accounting guidance is not expected to have a material impact on our consolidated financial statements or financial statement disclosures. | |
Stock_options
Stock options | 12 Months Ended | |||||||||||
Dec. 31, 2013 | ||||||||||||
Stock Options Abstract | ' | |||||||||||
Stock options | ' | |||||||||||
3. Stock options | ||||||||||||
The Compensation Committee of the Board of Directors administers the Company’s stock option plan. The Compensation Committee designates eligible participants to be included under the plan and approves the number of options to be granted from time to time under the plan. On June 24, 2010, at the Company’s annual meeting, shareholders approved an amendment to the Company’s Stock Option Plan (the “Plan Maximum Amendment”). The Plan Maximum Amendment relates to changing the maximum number of shares of common stock issuable under the Stock Option Plan from a fixed number of 20,000 to the number of shares that represent twenty five percent (25%) of the total number of all issued and outstanding shares of common stock from time to time. Based upon the current shares outstanding, a maximum of 7,290 options are authorized for issuance under the plan. The option exercise price for all options issued under the plan is based on the fair value of the underlying shares on the date of grant. All options vest within three years or less and are exercisable for a period of seven years from the date of grant. The stock option plan, as amended, allows the issuance of Canadian and U.S. dollar grants. A summary of the stock option transactions, for both the Canadian and U.S. dollar grants, through the year ended December 31, 2013 is below. | ||||||||||||
The following options granted under the stock option plan are exercisable in Canadian dollars: | ||||||||||||
Exercise Price in Canadian | ||||||||||||
Dollars | ||||||||||||
Number of | Range | Weighted- | ||||||||||
Options | average | |||||||||||
Outstanding at December 31, 2011 | 4,171 | 0.54-0.81 | $ | 0.78 | ||||||||
Granted | - | - | - | |||||||||
Exercised | - | - | - | |||||||||
Forfeited or expired | - | - | - | |||||||||
Outstanding at December 31, 2012 | 4,171 | 0.54-0.81 | 0.78 | |||||||||
Granted | - | - | - | |||||||||
Exercised | - | - | - | |||||||||
Forfeited or expired | -78 | 0.81 | 0.81 | |||||||||
Outstanding at December 31, 2013 | 4,093 | $ | 0.54-0.81 | $ | 0.79 | |||||||
Price in Canadian Dollars | # outstanding and | Weighted average remaining life (years) | ||||||||||
exercisable at | ||||||||||||
December 31, 2013 | ||||||||||||
$ | 0.54 | 88 | 4.26 | |||||||||
$ | 0.63 | 303 | 4.21 | |||||||||
$ | 0.81 | 3,702 | 3.97 | |||||||||
TOTAL | 4,093 | 3.99 | ||||||||||
The following options granted under the stock option plan are exercisable in U.S. dollars: | ||||||||||||
Exercise Price in U.S. Dollars | ||||||||||||
Number of | Range | Weighted- | ||||||||||
Options | average | |||||||||||
Outstanding at December 31, 2011 | 963 | $ | 0.50 - 24.30 | $ | 8.51 | |||||||
Granted | 1,137 | 0.15 - 0.56 | 0.32 | |||||||||
Exercised | - | - | - | |||||||||
Forfeited or expired | -773 | 5.04 – 24.30 | 9.92 | |||||||||
Outstanding at December 31, 2012 | 1,327 | 0.15 - 11.34 | 0.67 | |||||||||
Granted | 315 | 0.24 - 0.98 | 0.32 | |||||||||
Exercised | - | - | - | |||||||||
Forfeited or expired | -11 | 5.22 - 10.26 | 10.14 | |||||||||
Outstanding at December 31, 2013 | 1,631 | $ | 0.15-10.26 | $ | 0.6 | |||||||
Price in US Dollars | # Outstanding and | Remaining life | ||||||||||
Exercisable at | (years) | |||||||||||
December 31, 2013 | ||||||||||||
$ | 0.15 | 33 | 5.71 | |||||||||
$ | 0.18 | 61 | 5.45 | |||||||||
$ | 0.2 | 254 | 5.33 | |||||||||
$ | 0.24 | 250 | 6.74 | |||||||||
$ | 0.32 | 31 | 6.71 | |||||||||
$ | 0.35 | 689 | 5.97 | |||||||||
$ | 0.5 | 94 | 4.95 | |||||||||
$ | 0.56 | 100 | 6.05 | |||||||||
$ | 0.63 | 44 | 4.7 | |||||||||
$ | 0.8 | 25 | 6.35 | |||||||||
$ | 0.98 | 10 | 6.47 | |||||||||
$ | 1.8 | 4 | 1.73 | |||||||||
$ | 5.04 | 7 | 0.23 | |||||||||
$ | 5.22 | 2 | 1.42 | |||||||||
$ | 7.2 | 2 | 0.71 | |||||||||
$ | 10.26 | 12 | 0.38 | |||||||||
$ | 11.34 | 13 | 0.13 | |||||||||
1,631 | 5.73 | |||||||||||
Stock compensation expense for the fiscal years ended December 31, 2013 and 2012 was $87 and $326 respectively. These amounts have been included in the general and administrative expenses for the respective periods. The weighted average fair value per share of options granted during the fiscal years ended December 31, 2013 and 2012 was $0.32 and $0.32, respectively. The intrinsic value (being the difference between the share price as at December 31, 2013 and exercise price) of stock options outstanding at December 31, 2013 was NIL. | ||||||||||||
The fair values of options granted in fiscal years ended December 31, 2013 and 2012 were estimated on the date the options were granted based on the Black-Scholes option-pricing model, using the following weighted average assumptions: | ||||||||||||
Year Ended | Year Ended | |||||||||||
December 31, | December 31, | |||||||||||
2013 | 2012 | |||||||||||
Expected dividend | 0 | % | 0 | % | ||||||||
Risk-free interest rate | 1.10-1.73 | % | 1.09–1.26 | % | ||||||||
Expected volatility | 144-175 | % | 118-133 | % | ||||||||
Expected life | 7 years | 7 years | ||||||||||
The Company uses the historical volatility and adjusts for available relevant market information pertaining to the Company’s share price. | ||||||||||||
Derivative_Liabilities
Derivative Liabilities | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Derivative Instruments [Abstract] | ' | |||||||
Derivative Instruments | ' | |||||||
4. Derivative Liabilities | ||||||||
Effective January 1, 2009, the Company adopted ASC Topic 815-40, "Derivatives and Hedging" (ASC 815-40). One of the conclusions reached under ASC 815-40 was that an equity-linked financial instrument would not be considered indexed to the entity's own stock if the strike price is denominated in a currency other than the issuer's functional currency. The conclusion reached under ASC 815-40 clarified the accounting treatment for these and certain other financial instruments. ASC 815-40 specifies that a contract would not be treated as a derivative if it met the following conditions: (a) indexed to the Company's own stock; and (b) classified in shareholders' equity in the Company's statement of financial position. The Company's outstanding warrants denominated in Canadian dollars are not considered to be indexed to its own stock because the exercise price is denominated in Canadian dollars and the Company's functional currency is United States dollars. Therefore, these warrants have been treated as derivative financial instruments and recorded at their fair value as a liability. All other outstanding convertible instruments are considered to be indexed to the Company's stock, because their exercise price is denominated in the same currency as the Company's functional currency, and are included in stockholders' deficiency. | ||||||||
The Company's derivative instruments include warrants to purchase 18,035 shares, the exercise prices for which are denominated in a currency other than the Company's functional currency, as follows: | ||||||||
· | Warrants to purchase 13,337 shares at CAD$1.44 per whole share that expire on April 30, 2015; and | |||||||
· | Warrants to purchase 4,698 shares exercisable at CAD$1.44 per whole share that expire on March 29, 2016. | |||||||
These warrants have been recorded at their fair value as a liability at issuance and will continue to be re-measured at fair value as a liability at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as unrealized gain/(loss). These warrants will continue to be reported as a liability until such time as they are exercised or expire. The fair value of these warrants is estimated using the Black-Scholes option-pricing model. | ||||||||
As of December 31, 2013, the fair value of the warrants expiring April 30, 2015 and March 29, 2016 was determined to be $2,015 and $794 respectively (December 31, 2012 – warrants expiring April 30, 2015, fair value of $4,698, March 29, 2016, fair value of $1,847), and the gain on these warrants for the twelve months ended December 31, 2013 was $2,683 and $1,052, respectively (December 31, 2012 - warrants expiring April 30, 2015, loss of $1,026; March 29, 2016, gain of $507). There is no cash flow impact for these derivatives until the warrants are exercised. If these warrants are exercised, the Company will receive the proceeds from the exercise at the current exchange rate at the time of exercise. | ||||||||
Gain/(Loss) on Derivative Instruments | Twelve months ended December 31, 2013 | Twelve months ended December 31, 2012 | ||||||
Warrant expiring April 15, 2015 | 2,683 | -1,026 | ||||||
Warrant expiring March 29, 2016 | 1,052 | -507 | ||||||
Rights offering derivative | - | - | ||||||
Options to contractors | 42 | -30 | ||||||
Total | 3,777 | -1,563 | ||||||
During the fiscal year ended December 31, 2011, the Company issued 108 options to contractors with a Canadian dollar denominated strike price. Consequently, the Company now has derivatives relating to these options since the strike price is denominated in a currency other than the US dollar functional currency of the Company. While there is an exception to this rule for employees in ASU 2010-13 "Compensation-Stock Compensation (Topic 718):Effect of Denominating the exercise price of a share based payment award in the currency of the market in which the underlying equity security trades", no such exception exists for contractors. These options will be marked to market until the earlier of their expiry or exercise. The fair value of these options at December 31, 2013 and December 31, 2012 was $54 and $96 respectively. The gain for the twelve months ended December 31, 2013 and December 31, 2012 was $42 and a loss of $30 respectively. | ||||||||
Fair_Value_Measurements
Fair Value Measurements | 12 Months Ended | |||||||||||||
Dec. 31, 2013 | ||||||||||||||
Fair Value Disclosures [Abstract] | ' | |||||||||||||
Fair Value Measurements | ' | |||||||||||||
5. Fair Value Measurements | ||||||||||||||
The Company has adopted Fair Value Measurements and Disclosure Topic of the FASB. This Topic applies to certain assets and liabilities that are being measured and reported on a fair value basis. The Fair Value Measurements Topic defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosure about fair value measurements. This Topic enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The Topic requires that financial assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: | ||||||||||||||
Level 1: Quoted market prices in active markets for identical assets or liabilities. | ||||||||||||||
Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data. | ||||||||||||||
Level 3: Unobservable inputs that are not corroborated by market data. | ||||||||||||||
Assets/Liabilities Measured at Fair Value on a Recurring Basis | ||||||||||||||
Fair Value Measurement at December 31, 2013 | ||||||||||||||
Quoted Price in Active Markets | Significant Other | Significant | ||||||||||||
for Identical Instruments | Observable Inputs | Unobservable Inputs | ||||||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||||
Assets | ||||||||||||||
Cash equivalents | $ | - | $ | 1,663 | $ | - | $ | 1,663 | ||||||
Liabilities | ||||||||||||||
Derivative liabilities | - | 2,863 | - | 2,863 | ||||||||||
The Company's financial instruments include cash equivalents and derivative liabilities. Only cash equivalents and derivative liabilities are carried at their fair value. The derivative liabilities include warrants denominated in a currency other than the Company’s functional currency and options issued to contractors in a currency other than the functional currency of the Company. The warrants are carried at fair value and calculated using the Black-Scholes option pricing model using the following assumptions; expected dividend 0%; risk-free interest rate of 1.10%-1.73%; expected volatility of 144% - 175%; and a 1.3 or 2.2 year remaining life. The options also use the Black Scholes model with the following assumptions: expected dividend 0%; risk-free interest rate of 1.43%-1.46% expected volatility of 154%- 172%; and a 3.9-4.4 year remaining life. The risk free rate was based on Bank of Canada Bond issues of similar term. Expected volatility was estimated by using historical volatility of weekly close share prices for a period equal to the remaining life of the instrument. | ||||||||||||||
Shareholders_Equity
Shareholders' Equity | 12 Months Ended | |||||||||
Dec. 31, 2013 | ||||||||||
Stockholders' Equity [Abstract] | ' | |||||||||
Shareholders' Equity | ' | |||||||||
6. Shareholders’ Equity | ||||||||||
Authorized capital stock | ||||||||||
The Company’s authorized capital stock consists of an unlimited number of shares of no par common stock. | ||||||||||
On August 10, 2011, the Board of Directors approved a 1-for-18 reverse stock split, or “share consolidation”, which became effective on August 25, 2011. The 1-for-18 reverse stock split affected all of the Company’s common shares, stock options and warrants outstanding at the effective date. Consequently, the Company has retroactively adjusted its financial statements for all periods presented to show the share shares, stock options and warrants as if they had always been presented on this basis. The number of units and unit prices (including with respect to the units issued in our 2011 Private Placement and the Rights Offering) have not been adjusted to reflect the Share Consolidation, and the number of warrants outstanding have not been adjusted to reflect the Share Consolidation (in accordance with the terms of the warrants, the number of shares of common stock issuable thereunder were adjusted as a result of the Share Consolidation but not the number of warrants outstanding). | ||||||||||
Equity financings | ||||||||||
On November 22, 2013, the Company completed the closing of non-brokered private placement (the “Offering”) of 4,000 units for gross proceeds of US$1,600. Each unit (a “Unit”) was issued at a price of $0.40 per Unit and consisted of one common share of the Company (the “Common Shares”) and one common share purchase warrant (the “Warrants”). Each Warrant entitles the holder thereof to acquire one Common Share at a price of US$0.50 per share for a period of five years from the date of issuance. | ||||||||||
Warrants to Purchase Common Stock | ||||||||||
At December 31, 2013, the Company had the following warrants outstanding to purchase common stock priced in Canadian dollars with a weighted average exercise price of $1.44 and a weighted average remaining life of 2.6 years. The Company also had warrants outstanding to purchase common stock priced in U.S. dollars with a weighted average price of $0.50 and a weighted average remaining life of 6.9 years: | ||||||||||
Warrant Description | Common Shares Issuable Upon | |||||||||
Exercise of Outstanding | ||||||||||
(Warrants in thousands) | Warrants at December 31, 2013 | Exercise Price CND/USD | Expiration Date | |||||||
Investor Warrants (1) | 13,337 | $ | 1.44 CND | 30-Apr-15 | ||||||
Investor Warrants (2) | 4,698 | $ | 1.44 CND | 29-Mar-16 | ||||||
Investor Warrants (3) | 4,000 | $ | 0.50 USD | 22-Nov-20 | ||||||
22,035 | ||||||||||
(1) On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement (“Private Placement”) of 240,066 units, at a price of $0.03 CAD per unit for net proceeds of CAD$7,200. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date. | ||||||||||
(2) On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of $0.03 CAD per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date. | ||||||||||
Research_and_Development
Research and Development | 12 Months Ended | ||||||||||
Dec. 31, 2013 | |||||||||||
Research and Development [Abstract] | ' | ||||||||||
Research and Development | ' | ||||||||||
7. Research and Development | |||||||||||
Investment tax credits earned as a result of qualifying research and development expenditures and government grants have been applied to reduce research and development expenses as follows: | |||||||||||
Year Ended | Year Ended | Cumulative From | |||||||||
December 31, | December 31, | September 3, 1996 to | |||||||||
December 31, | |||||||||||
2013 | 2012 | 2013 | |||||||||
Research and development | $ | 579 | $ | 2,075 | $ | 69,746 | |||||
Investment tax credits | - | - | -1,632 | ||||||||
National Research Council grants | - | - | -197 | ||||||||
$ | 579 | $ | 2,075 | $ | 67,917 | ||||||
Commitments_and_Contingencies
Commitments and Contingencies | 12 Months Ended | ||||||||||
Dec. 31, 2013 | |||||||||||
Commitments [Abstract] | ' | ||||||||||
Commitments and Contingencies | ' | ||||||||||
8. Commitments and Contingencies | |||||||||||
LifeSci Advisors, LLC. | |||||||||||
The Company has a service agreement with LifeSci Advisors, LLC under which it is required to make several payments over the course of the agreement. LifeSci Advisors, LLC services include, but are not limited to, an investor meeting program and creating a key message platform. | |||||||||||
Less than | 3-Jan | Total | |||||||||
1 year | years | ||||||||||
LifeSci Advisors, LLC | 55 | - | 55 | ||||||||
Total | $ | 55 | $ | - | $ | 55 | |||||
Oregon Health & Science University Agreement | |||||||||||
On February 20, 2013, Adherex entered into a new exclusive license agreement with Oregon Health & Science University (“OHSU”) for exclusive worldwide license rights to intellectual property directed to thiol-based compounds, including STS and their use in oncology (the "New OHSU Agreement"). OHSU will receive certain milestone payments, a 2.5 percent royalty on net sales for licensed products which can be reduced to 1.0 percent upon a $150,000 buy down and a 5 percent royalty on any consideration received from sublicensing of the licensed technology. Milestone payment fees payable to OHSU include $100,000 upon first commercial sale for any licensed product. | |||||||||||
On February 20, 2013, Adherex terminated the previous exclusive license agreement with OHSU and Oxiquant a wholly owned subsidiary of Adherex, dated September 26, 2002 (the "Previous OHSU Agreement"). Pursuant to the Previous OHSU Agreement, OHSU granted Oxiquant an exclusive worldwide license to intellectual property directed to thiol-based compounds including STS and their use in oncology. In consideration, OHSU was issued 13,902 shares of common stock of Oxiquant that were subsequently converted upon the acquisition of Oxiquant into 21,250 shares of Adherex common stock, and warrants to purchase shares of Adherex common stock that subsequently expired in 2007. | |||||||||||
The term of the New OHSU Agreement expires on the date of the last to expire claim(s) covered in the patents licensed to Adherex, unless earlier terminated as provided in the agreement. STS is currently protected by methods of use patents that the Company exclusively licensed from OHSU that expire in Europe in 2021 and are currently pending in the United States. The New OHSU Agreement is terminable by either Adherex or OHSU in the event of a material breach of the agreement by either party after 45 days prior written notice. Adherex also has the right to terminate the New OHSU Agreement at any time upon 60 days prior written notice and payment of all fees due to OHSU under the New OHSU Agreement. | |||||||||||
Subsequent_Events
Subsequent Events | 12 Months Ended |
Dec. 31, 2013 | |
Subsequent Events [Abstract] | ' |
Subsequent Events | ' |
9. Subsequent Events | |
Exercise of Stock Options | |
On March 5, 2014, Dr. Tom Spector exercised 150,000 options which were granted to him on November 20, 2012 pursuant to the Company's Amended and Restated Stock Option Plan at an aggregate exercise price of $52,500 or $0.35 per common share. On June 19, 2013 Dr. Spector resigned as Chief Scientific Officer of the Company. | |
Non-Executive Compensation | |
On January 24, 2014, the board approved an increase in non-executive compensation from $1,500 per meeting attended to $2,000 per meeting attended for both Chris Rallis and Steven Skolsky. There was no change to the non-cash compensation for Mr. Rallis or Mr. Skolsky. | |
Income_Taxes
Income Taxes | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Income Tax Disclosure [Abstract] | ' | ||||||||
Income Taxes | ' | ||||||||
10. Income Taxes | |||||||||
The Company operates in both U.S. and Canadian tax jurisdictions. Its income is subject to varying rates of tax and losses incurred in one jurisdiction cannot be used to offset income taxes payable in another. A reconciliation of the combined Canadian federal and provincial income tax rate with the Company’s effective tax rate is as follows: | |||||||||
Year Ended | Year Ended | ||||||||
December 31, | December 31, | ||||||||
2013 | 2012 | ||||||||
Domestic gain | 2,620 | -4,397 | |||||||
Foreign loss | -775 | -766 | |||||||
Gain before income taxes | 1,845 | -5,163 | |||||||
Expected statutory rate (recovery) | 26.5 | % | 26.5 | % | |||||
Expected provision for (recovery of) income tax | 489 | -1,368 | |||||||
Permanent differences | -977 | 489 | |||||||
Change in valuation allowance | 230 | 2,467 | |||||||
Non-refundable investment tax credits | - | - | |||||||
Effect of foreign exchange rate differences | 36 | -245 | |||||||
Effect of change in future enacted tax rates | - | -1,378 | |||||||
Effect of tax rate changes and other | 222 | 36 | |||||||
Provision for income taxes | $ | - | $ | - | |||||
The Canadian statutory come tax rate of 26.5 percent is comprised of federal income tax at approximately 15.5 percent and provincial income tax at approximately 11.0 percent. | |||||||||
The primary temporary differences which gave rise to future income taxes (recovery) at December 31, 2013, December 31, 2012: | |||||||||
December 31, | December 31, | ||||||||
2013 | 2012 | ||||||||
Future tax assets: | |||||||||
SR&ED expenditures | 2,195 | 2,195 | |||||||
Income tax loss carryforwards | 22,220 | 21,783 | |||||||
Non-refundable investment tax credits | 1,719 | 1,719 | |||||||
Share issue costs | 31 | 25 | |||||||
Accrued expenses | - | - | |||||||
Fixed and intangible assets | 1,006 | 970 | |||||||
Harmonization credit | - | 248 | |||||||
27,170 | 26,940 | ||||||||
Less: valuation allowance | -27,170 | -26,940 | |||||||
Net future tax assets | $ | - | $ | - | |||||
There are no current income taxes owed, nor are any income taxes expected to be owed in the near term. | |||||||||
At December 31, 2013 the Company has unclaimed Scientific Research and Experimental Development ("SR&ED") expenditures, income tax loss carry forwards and non-refundable investment tax credits. The unclaimed amounts and their expiry dates are as listed below: | |||||||||
Federal | Province/ | ||||||||
State | |||||||||
SR&ED expenditures (no expiry) | $ | 8,283 | $ | - | |||||
Income tax loss carryforwards (expiry date): | |||||||||
2014 | 6,089 | 6,089 | |||||||
2015 | 11,499 | 11,499 | |||||||
2021 | 26 | - | |||||||
2022 | 233 | - | |||||||
2023 | 133 | - | |||||||
2024 | 1,536 | 1,455 | |||||||
2025 | 4,795 | 4,768 | |||||||
2026 | 20,562 | 20,496 | |||||||
2027 | 8,340 | 8,320 | |||||||
2028 | 10,840 | 10,823 | |||||||
2029 | 8,502 | 8,502 | |||||||
2030 | 2,608 | 2,607 | |||||||
2031 | 3,377 | 3,377 | |||||||
2032 | 3,491 | 3,491 | |||||||
2033 | 1,817 | 1,817 | |||||||
Investment tax credits (expiry date): | |||||||||
2018 | 10 | ||||||||
2019 | 8 | ||||||||
2020 | 96 | ||||||||
2021 | 55 | ||||||||
2022 | 548 | ||||||||
2023 | 399 | ||||||||
2024 | 178 | ||||||||
2025 | 199 | ||||||||
2026 | 86 | ||||||||
2027 | 90 | ||||||||
2028 | 50 | ||||||||
Significant_Accounting_Policie1
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2013 | |
Significant Accounting Policies [Abstract] | ' |
Basis of presentation | ' |
Basis of presentation | |
The consolidated financial statements include the accounts of Adherex and of all its wholly-owned subsidiaries and all inter-company transactions and balances have been eliminated upon consolidation. | |
On August 10, 2011, the Board of Directors approved a 1-for-18 reverse stock split, or “Share Consolidation”, which became effective on August 25, 2011. The 1-for-18 reverse stock split affected all of the Company’s common shares, stock options and warrants outstanding at the effective date. Consequently, the Company has retroactively adjusted its financial statements for all periods presented to show the shares, stock options and warrants as if they had always been presented on this basis. The number of units and unit prices (including with respect to the units issued in our April 2010 Private Placement and the Rights Offering) have not been adjusted to reflect the Share Consolidation, and the number of warrants outstanding have not been adjusted to reflect the Share Consolidation (in accordance with the terms of the warrants, the number of shares of common stock issuable thereunder were adjusted as a result of the Share Consolidation but not the number of warrants outstanding). | |
Use of estimates | ' |
Use of estimates | |
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include the valuation of derivative warrant liability and the valuation of stock based compensation. Actual results could differ from those estimates. | |
Cash and cash equivalents | ' |
Cash and Cash Equivalents | |
Cash equivalents consist of highly liquid investments with original maturities at the date of purchase of three months or less. | |
The Company places its cash and cash equivalents in investments held by financial institutions in accordance with its investment policy designed to protect the principal investment. At December 31, 2013, the Company had $1,663 in cash accounts (2012- $2,303). Money market investments typically have minimal risk; however, in recent years the financial markets have been volatile resulting in concerns regarding money market investments. The Company has not experienced any loss or write-down of its money market investments. | |
Financial instruments | ' |
Financial instruments | |
Financial instruments recognized on the balance sheets at December 31, 2013 and December 31, 2012 consist of cash and cash equivalents, accounts payable, accrued liabilities and derivative liabilities, the carrying values of which, with the exception of the derivative liabilities, approximate fair value due to their relatively short time to maturity. The Company does not hold or issue financial instruments for trading. The derivative liabilities are carried at fair value. | |
The Company’s investment policy is to manage investments to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Investments, when made, are made in U.S. or Canadian bank securities, commercial paper of U.S. or Canadian industrial companies, utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed or carry ratings appropriate to the policy. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low for commercial paper. | |
The policy risks are primarily the opportunity cost of the conservative nature of the allowable investments. As the main purpose of the Company is research and development, the Company has chosen to avoid investments of a trade or speculative nature. | |
Common stock and warrants | ' |
Common stock and warrants | |
At December 31, 2007, the Company had warrants outstanding to purchase common stock that were denominated in both U.S. and Canadian dollars, which resulted in the Company having warrants outstanding that were denominated outside the Company’s U.S. dollar functional currency. | |
In November 2007, the Emerging Issues Task Force (“EITF”) of the FASB issued EITF No. 07-5, Issue Summary No.1 “Determining Whether an Instrument (or an Embedded Feature) is Indexed to an Entity's Own Stock” (“EITF 07-5”), codified as ASC 815-40. In June 2008, one of the conclusions reached under EITF 07-05 was a consensus that an equity-linked financial instrument would not be considered indexed to the entity's own stock if the strike price is denominated in a currency other than the issuer's functional currency. The issues brought to the EITF for discussion related to how an entity should determine whether certain instruments or embedded features are indexed to its own stock. This discussion included equity-linked financial instruments where the exercise price is denominated in a currency other than the issuer's functional currency; such as the Company’s outstanding warrants to purchase common stock that were denominated in Canadian dollars. This conclusion reached under EITF 07-05 clarified the accounting treatment for these and certain other financial instruments as it related to FASB Statement No. 133, “Accounting for Derivative Instruments and Hedging Activities” (“SFAS 133”), codified as ASC 815-10. SFAS 133 specifies that a contract that would otherwise meet the definition of a derivative under SFAS 133, issued or held by the reporting entity that is both (a) indexed to its own stock and (b) classified in stockholders' equity in its statement of financial position should not be considered a derivative financial instrument for purposes of applying SFAS 133. As a result, the Company’s outstanding warrants denominated in Canadian dollars were not considered to be indexed to its own stock and should therefore be treated as derivative financial instruments and recorded at their fair value as a liability. The Company issued further Canadian dollar denominated warrants on April 30, 2010 and March 29, 2011 and this resulted in warrants being shown as a liability which is marked to market as at December 31, 2013 and December 31, 2012. At December 31, 2013, the derivative liabilities were valued at $2,863 (2012: $6,640) and the unrealized gain on the value of the underlying securities was $3,777 (2012: loss $1,563) for the year ended December 31, 2013. | |
Revenue recognition | ' |
Revenue recognition | |
At this time, the Company does not have any revenue. | |
Research and development costs and investment tax credits | ' |
Research and development costs and investment tax credits | |
Research costs, including employee compensation, laboratory fees, lab supplies, and research and testing performed under contract by third parties, are expensed as incurred. Development costs, including drug substance costs, clinical study expenses and regulatory expenses are expensed as incurred. | |
Investment tax credits, which are earned as a result of qualifying research and development expenditures, are recognized when the expenditures are made and their realization is reasonably assured. They are applied to reduce related capital costs and research and development expenses in the year recognized. | |
Income taxes | ' |
Income taxes | |
The Company accounts for income taxes under the asset and liability method that requires the recognition of deferred tax assets or liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and tax basis of assets and liabilities. The Company provides a valuation allowance to reduce its deferred tax assets when it is more likely than not that such assets will not be realized. | |
The Company accounts for uncertainty in income taxes by following the Financial Accounting Standards Board issued Interpretation No. 48 (‘‘FIN 48’’), codified as ASC 740-10-25, ‘‘Accounting for Uncertainty in Income Taxes – an Interpretation of SFAS No. 109.’’ FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements in accordance with Statement of Financial Accounting Standards No. 109, ‘‘Accounting for Income Taxes.’, codified as ASC 740-10. FIN 48 provides guidance for how uncertain tax positions should be recognized, measured, presented and disclosed in the financial statements. FIN 48 requires the evaluation of tax positions taken or expected to be taken in the course of preparing tax returns to determine whether the tax positions have met a “more-likely-than-not” threshold of being sustained by the applicable tax authority. Tax benefits related to tax positions not deemed to meet the “more-likely-than-not” threshold are not permitted to be recognized in the financial statements. Upon adoption of FIN 48, the Company has elected an accounting policy that continues to classify accrued interest and penalties related to liabilities for income taxes in income tax expense. | |
Foreign currency translation | ' |
Foreign currency translation | |
The U.S. dollar is the functional currency for the Company’s consolidated operations. For those entities, all gains and losses from currency translations are included in results of operations. | |
Earnings/(Loss) per share | ' |
Earnings/(Loss) per share | |
Basic net earnings/(loss) per share is computed by dividing net earnings/(loss) by the weighted average number of shares of common stock outstanding during the year. Diluted net earnings per share is computed using the same method, except the weighted average number shares of common stock outstanding includes convertible debentures, stock options and warrants, if dilutive as determined using the if-converted method and treasury methods. Accordingly, options to purchase 5,319 and warrants to purchase 21,665 shares at December 31, 2013, were not included in earnings per share. These options and warrant were not included in the computation of diluted earnings per share because the exercise prices were greater than the average market price of the common shares at that date, and accordingly, such options would have an antidilutive effect. In 2012 we incurred a net loss and accordingly none of the options or warrants outstanding, 5,498 and 18,385, respectively, were included in loss per share because their effect would be antidilutive. | |
Newly adopted accounting pronouncements | ' |
Newly adopted accounting pronouncements | |
In February 2013, the FASB issued ASU 2013-02 to improve the reporting of reclassifications out of accumulated other comprehensive income. The ASU provides amendments to the Comprehensive Income subtopic of the FASB ASC, such that companies must report the effect of significant reclassifications out of accumulated comprehensive income on the respective line items in net income. For other amounts that are not required to be reclassified in their entirety to net income, an entity may cross reference to the relevant note disclosure. The Company was required to adopt this ASU in the first quarter for fiscal 2013. The adoption of this standard did not have a significant impact on the Company’s reporting. | |
Recent accounting pronouncements | ' |
Recent accounting pronouncements | |
In July 2013, the FASB issued ASU No. 2013-11, "Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists," an amendment to FASB Accounting Standards Codification, or "ASC" Topic 740, Income Taxes, or "FASB ASC Topic 740." This update clarifies that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed. In situations where a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction or the tax law of the jurisdiction does not require, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. This ASU is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption and retrospective application are permitted. This accounting guidance is not expected to have a material impact on our consolidated financial statements or financial statement disclosures. | |
Stock_options_Tables
Stock options (Tables) | 12 Months Ended | |||||||||||
Dec. 31, 2013 | ||||||||||||
Fair values of options granted using weighted average assumptions | ' | |||||||||||
The fair values of options granted in fiscal years ended December 31, 2013 and 2012 were estimated on the date the options were granted based on the Black-Scholes option-pricing model, using the following weighted average assumptions: | ||||||||||||
Year Ended | Year Ended | |||||||||||
December 31, | December 31, | |||||||||||
2013 | 2012 | |||||||||||
Expected dividend | 0 | % | 0 | % | ||||||||
Risk-free interest rate | 1.10-1.73 | % | 1.09–1.26 | % | ||||||||
Expected volatility | 144-175 | % | 118-133 | % | ||||||||
Expected life | 7 years | 7 years | ||||||||||
Currency, Canadian Dollar [Member] | ' | |||||||||||
Options granted under the stock option plan are exercisable | ' | |||||||||||
The following options granted under the stock option plan are exercisable in Canadian dollars: | ||||||||||||
Exercise Price in Canadian | ||||||||||||
Dollars | ||||||||||||
Number of | Range | Weighted- | ||||||||||
Options | average | |||||||||||
Outstanding at December 31, 2011 | 4,171 | 0.54-0.81 | $ | 0.78 | ||||||||
Granted | - | - | - | |||||||||
Exercised | - | - | - | |||||||||
Forfeited or expired | - | - | - | |||||||||
Outstanding at December 31, 2012 | 4,171 | 0.54-0.81 | 0.78 | |||||||||
Granted | - | - | - | |||||||||
Exercised | - | - | - | |||||||||
Forfeited or expired | -78 | 0.81 | 0.81 | |||||||||
Outstanding at December 31, 2013 | 4,093 | $ | 0.54-0.81 | $ | 0.79 | |||||||
Options reinstated agreement either expired and cancelled prior to the agreed severance | ' | |||||||||||
Price in Canadian Dollars | # outstanding and | Weighted average remaining life (years) | ||||||||||
exercisable at | ||||||||||||
December 31, 2013 | ||||||||||||
$ | 0.54 | 88 | 4.26 | |||||||||
$ | 0.63 | 303 | 4.21 | |||||||||
$ | 0.81 | 3,702 | 3.97 | |||||||||
TOTAL | 4,093 | 3.99 | ||||||||||
Currency, U.S. Dollar [Member] | ' | |||||||||||
Options granted under the stock option plan are exercisable | ' | |||||||||||
The following options granted under the stock option plan are exercisable in U.S. dollars: | ||||||||||||
Exercise Price in U.S. Dollars | ||||||||||||
Number of | Range | Weighted- | ||||||||||
Options | average | |||||||||||
Outstanding at December 31, 2011 | 963 | $ | 0.50 - 24.30 | $ | 8.51 | |||||||
Granted | 1,137 | 0.15 - 0.56 | 0.32 | |||||||||
Exercised | - | - | - | |||||||||
Forfeited or expired | -773 | 5.04 – 24.30 | 9.92 | |||||||||
Outstanding at December 31, 2012 | 1,327 | 0.15 - 11.34 | 0.67 | |||||||||
Granted | 315 | 0.24 - 0.98 | 0.32 | |||||||||
Exercised | - | - | - | |||||||||
Forfeited or expired | -11 | 5.22 - 10.26 | 10.14 | |||||||||
Outstanding at December 31, 2013 | 1,631 | $ | 0.15-10.26 | $ | 0.6 | |||||||
Options reinstated agreement either expired and cancelled prior to the agreed severance | ' | |||||||||||
Price in US Dollars | # Outstanding and | Remaining life | ||||||||||
Exercisable at | (years) | |||||||||||
December 31, 2013 | ||||||||||||
$ | 0.15 | 33 | 5.71 | |||||||||
$ | 0.18 | 61 | 5.45 | |||||||||
$ | 0.2 | 254 | 5.33 | |||||||||
$ | 0.24 | 250 | 6.74 | |||||||||
$ | 0.32 | 31 | 6.71 | |||||||||
$ | 0.35 | 689 | 5.97 | |||||||||
$ | 0.5 | 94 | 4.95 | |||||||||
$ | 0.56 | 100 | 6.05 | |||||||||
$ | 0.63 | 44 | 4.7 | |||||||||
$ | 0.8 | 25 | 6.35 | |||||||||
$ | 0.98 | 10 | 6.47 | |||||||||
$ | 1.8 | 4 | 1.73 | |||||||||
$ | 5.04 | 7 | 0.23 | |||||||||
$ | 5.22 | 2 | 1.42 | |||||||||
$ | 7.2 | 2 | 0.71 | |||||||||
$ | 10.26 | 12 | 0.38 | |||||||||
$ | 11.34 | 13 | 0.13 | |||||||||
1,631 | 5.73 | |||||||||||
Derivative_Liabilities_Tables
Derivative Liabilities (Tables) | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Derivative Instruments [Abstract] | ' | |||||||
Gain Loss on Derivative Instruments | ' | |||||||
Gain/(Loss) on Derivative Instruments | Twelve months ended December 31, 2013 | Twelve months ended December 31, 2012 | ||||||
Warrant expiring April 15, 2015 | 2,683 | -1,026 | ||||||
Warrant expiring March 29, 2016 | 1,052 | -507 | ||||||
Rights offering derivative | - | - | ||||||
Options to contractors | 42 | -30 | ||||||
Total | 3,777 | -1,563 | ||||||
Fair_Value_Measurements_Tables
Fair Value Measurements (Tables) | 12 Months Ended | |||||||||||||
Dec. 31, 2013 | ||||||||||||||
Fair Value Disclosures [Abstract] | ' | |||||||||||||
Assets/Liabilities Measured at Fair Value on Recurring Basis | ' | |||||||||||||
Assets/Liabilities Measured at Fair Value on a Recurring Basis | ||||||||||||||
Fair Value Measurement at December 31, 2013 | ||||||||||||||
Quoted Price in Active Markets | Significant Other | Significant | ||||||||||||
for Identical Instruments | Observable Inputs | Unobservable Inputs | ||||||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||||
Assets | ||||||||||||||
Cash equivalents | $ | - | $ | 1,663 | $ | - | $ | 1,663 | ||||||
Liabilities | ||||||||||||||
Derivative liabilities | - | 2,863 | - | 2,863 | ||||||||||
Shareholders_Equity_Tables
Shareholders' Equity (Tables) | 12 Months Ended | |||||||||
Dec. 31, 2013 | ||||||||||
Warrants Outstanding to Purchase Common Stock | ' | |||||||||
At December 31, 2013, the Company had the following warrants outstanding to purchase common stock priced in Canadian dollars with a weighted average exercise price of $1.44 and a weighted average remaining life of 2.6 years. The Company also had warrants outstanding to purchase common stock priced in U.S. dollars with a weighted average price of $0.50 and a weighted average remaining life of 6.9 years: | ||||||||||
Warrant Description | Common Shares Issuable Upon | |||||||||
Exercise of Outstanding | ||||||||||
(Warrants in thousands) | Warrants at December 31, 2013 | Exercise Price CND/USD | Expiration Date | |||||||
Investor Warrants (1) | 13,337 | $ | 1.44 CND | 30-Apr-15 | ||||||
Investor Warrants (2) | 4,698 | $ | 1.44 CND | 29-Mar-16 | ||||||
Investor Warrants (3) | 4,000 | $ | 0.50 USD | 22-Nov-20 | ||||||
22,035 | ||||||||||
(1) On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement (“Private Placement”) of 240,066 units, at a price of $0.03 CAD per unit for net proceeds of CAD$7,200. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date. | ||||||||||
(2) On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of $0.03 CAD per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a “Warrant”). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date. | ||||||||||
Research_and_Development_Table
Research and Development (Tables) | 12 Months Ended | ||||||||||
Dec. 31, 2013 | |||||||||||
Research and Development [Abstract] | ' | ||||||||||
Research and Development | ' | ||||||||||
Investment tax credits earned as a result of qualifying research and development expenditures and government grants have been applied to reduce research and development expenses as follows: | |||||||||||
Year Ended | Year Ended | Cumulative From | |||||||||
December 31, | December 31, | September 3, 1996 to | |||||||||
December 31, | |||||||||||
2013 | 2012 | 2013 | |||||||||
Research and development | $ | 579 | $ | 2,075 | $ | 69,746 | |||||
Investment tax credits | - | - | -1,632 | ||||||||
National Research Council grants | - | - | -197 | ||||||||
$ | 579 | $ | 2,075 | $ | 67,917 | ||||||
Commitments_and_Contingencies_
Commitments and Contingencies (Tables) | 12 Months Ended | ||||||||||
Dec. 31, 2013 | |||||||||||
Commitments [Abstract] | ' | ||||||||||
Commitments and Contingencies | ' | ||||||||||
The Company has a service agreement with LifeSci Advisors, LLC under which it is required to make several payments over the course of the agreement. LifeSci Advisors, LLC services include, but are not limited to, an investor meeting program and creating a key message platform. | |||||||||||
Less than | 3-Jan | Total | |||||||||
1 year | years | ||||||||||
LifeSci Advisors, LLC | 55 | - | 55 | ||||||||
Total | $ | 55 | $ | - | $ | 55 | |||||
Income_Taxes_Tables
Income Taxes (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Income Tax Disclosure [Abstract] | ' | ||||||||
Reconciliation of the combined income tax rate | ' | ||||||||
A reconciliation of the combined Canadian federal and provincial income tax rate with the Company’s effective tax rate is as follows: | |||||||||
Year Ended | Year Ended | ||||||||
December 31, | December 31, | ||||||||
2013 | 2012 | ||||||||
Domestic gain | 2,620 | -4,397 | |||||||
Foreign loss | -775 | -766 | |||||||
Gain before income taxes | 1,845 | -5,163 | |||||||
Expected statutory rate (recovery) | 26.5 | % | 26.5 | % | |||||
Expected provision for (recovery of) income tax | 489 | -1,368 | |||||||
Permanent differences | -977 | 489 | |||||||
Change in valuation allowance | 230 | 2,467 | |||||||
Non-refundable investment tax credits | - | - | |||||||
Effect of foreign exchange rate differences | 36 | -245 | |||||||
Effect of change in future enacted tax rates | - | -1,378 | |||||||
Effect of tax rate changes and other | 222 | 36 | |||||||
Provision for income taxes | $ | - | $ | - | |||||
Summary Of Tax Credit Carryforwards | ' | ||||||||
The primary temporary differences which gave rise to future income taxes (recovery) at December 31, 2013, December 31, 2012: | |||||||||
December 31, | December 31, | ||||||||
2013 | 2012 | ||||||||
Future tax assets: | |||||||||
SR&ED expenditures | 2,195 | 2,195 | |||||||
Income tax loss carryforwards | 22,220 | 21,783 | |||||||
Non-refundable investment tax credits | 1,719 | 1,719 | |||||||
Share issue costs | 31 | 25 | |||||||
Accrued expenses | - | - | |||||||
Fixed and intangible assets | 1,006 | 970 | |||||||
Harmonization credit | - | 248 | |||||||
27,170 | 26,940 | ||||||||
Less: valuation allowance | -27,170 | -26,940 | |||||||
Net future tax assets | $ | - | $ | - | |||||
The unclaimed amounts and their expiry dates are as listed below: | |||||||||
Federal | Province/ | ||||||||
State | |||||||||
SR&ED expenditures (no expiry) | $ | 8,283 | $ | - | |||||
Income tax loss carryforwards (expiry date): | |||||||||
2014 | 6,089 | 6,089 | |||||||
2015 | 11,499 | 11,499 | |||||||
2021 | 26 | - | |||||||
2022 | 233 | - | |||||||
2023 | 133 | - | |||||||
2024 | 1,536 | 1,455 | |||||||
2025 | 4,795 | 4,768 | |||||||
2026 | 20,562 | 20,496 | |||||||
2027 | 8,340 | 8,320 | |||||||
2028 | 10,840 | 10,823 | |||||||
2029 | 8,502 | 8,502 | |||||||
2030 | 2,608 | 2,607 | |||||||
2031 | 3,377 | 3,377 | |||||||
2032 | 3,491 | 3,491 | |||||||
2033 | 1,817 | 1,817 | |||||||
Investment tax credits (expiry date): | |||||||||
2018 | 10 | ||||||||
2019 | 8 | ||||||||
2020 | 96 | ||||||||
2021 | 55 | ||||||||
2022 | 548 | ||||||||
2023 | 399 | ||||||||
2024 | 178 | ||||||||
2025 | 199 | ||||||||
2026 | 86 | ||||||||
2027 | 90 | ||||||||
2028 | 50 | ||||||||
Going_Concern_Additional_Infor
Going Concern - Additional Information (Details) (USD $) | 12 Months Ended | 208 Months Ended | |
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 |
Going Concern [Line Items] | ' | ' | ' |
Loss from operations | ($1,931) | ($3,620) | ($116,176) |
Net cash used in operating activities | 2,210 | 2,994 | 87,247 |
Deficit accumulated during development stage | $108,698 | $110,543 | $108,698 |
Significant_Accounting_Policie2
Significant Accounting Policies - Additional Information (Details) (USD $) | 12 Months Ended | 208 Months Ended | |||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2011 | Sep. 02, 1996 |
Summary Of Significant Accounting Policies [Line Items] | ' | ' | ' | ' | ' |
Cash and cash equivalents - Beginning of period | $1,663 | $2,303 | $1,663 | $5,297 | $0 |
Derivative liability | 2,863 | 6,640 | 2,863 | ' | ' |
Gain/(loss) on derivative warrants | $3,777 | ($1,563) | $7,034 | ' | ' |
Warrant [Member] | ' | ' | ' | ' | ' |
Summary Of Significant Accounting Policies [Line Items] | ' | ' | ' | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 21,665 | 18,385 | ' | ' | ' |
Stock Option [Member] | ' | ' | ' | ' | ' |
Summary Of Significant Accounting Policies [Line Items] | ' | ' | ' | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 5,319 | 5,498 | ' | ' | ' |
Stock_Options_Options_Granted_
Stock Options (Options Granted Under The Stock Option Plan Exercisable In Canadian Dollars And U.S Dollars) (Details) | 12 Months Ended | 12 Months Ended | 12 Months Ended | |||||||||
In Thousands, except Per Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 |
Stock Option In Canadian Dollars [Member] | Stock Option In Canadian Dollars [Member] | Stock Option In Us Dollars [Member] | Stock Option In Us Dollars [Member] | Minimum [Member] | Minimum [Member] | Minimum [Member] | Minimum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | |
CAD | CAD | USD ($) | USD ($) | Stock Option In Canadian Dollars [Member] | Stock Option In Canadian Dollars [Member] | Stock Option In Us Dollars [Member] | Stock Option In Us Dollars [Member] | Stock Option In Canadian Dollars [Member] | Stock Option In Canadian Dollars [Member] | Stock Option In Us Dollars [Member] | Stock Option In Us Dollars [Member] | |
CAD | CAD | USD ($) | USD ($) | CAD | CAD | USD ($) | USD ($) | |||||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Outstanding Number of Options | 4,171 | 4,171 | 1,327 | 963 | ' | ' | ' | ' | ' | ' | ' | ' |
Granted Number of Options | 0 | 0 | 315 | 1,137 | ' | ' | ' | ' | ' | ' | ' | ' |
Exercised Number of Options | 0 | 0 | 0 | 0 | ' | ' | ' | ' | ' | ' | ' | ' |
Forfeited or expired Number of Options | -78 | 0 | -11 | -773 | ' | ' | ' | ' | ' | ' | ' | ' |
Outstanding Number of Options | 4,093 | 4,171 | 1,631 | 1,327 | ' | ' | ' | ' | ' | ' | ' | ' |
Outstanding Range | ' | ' | ' | ' | 0.54 | 0.54 | $0.15 | $0.50 | 0.81 | 0.81 | $11.34 | $24.30 |
Granted Range | 0 | 0 | ' | ' | ' | ' | $0.24 | $0.15 | ' | ' | $0.98 | $0.56 |
Exercised Range | 0 | 0 | $0 | $0 | ' | ' | $0.24 | ' | ' | ' | $0.98 | ' |
Forfeited or expired Range | 0.81 | 0 | ' | ' | ' | ' | $5.22 | $5.04 | ' | ' | $10.26 | $24.30 |
Outstanding Range | ' | ' | ' | ' | 0.54 | 0.54 | $0.15 | $0.15 | 0.81 | 0.81 | $10.26 | $11.34 |
Outstanding Weighted- average | 0.78 | 0.78 | $0.67 | $8.51 | ' | ' | ' | ' | ' | ' | ' | ' |
Granted Weighted- average | 0 | 0 | $0.32 | $0.32 | ' | ' | ' | ' | ' | ' | ' | ' |
Exercised Weighted- average | 0 | 0 | $0 | $0 | ' | ' | ' | ' | ' | ' | ' | ' |
Forfeited or expired Weighted- average | 0.81 | 0 | $10.14 | $9.92 | ' | ' | ' | ' | ' | ' | ' | ' |
Outstanding Weighted- average | 0.79 | 0.78 | $0.60 | $0.67 | ' | ' | ' | ' | ' | ' | ' | ' |
Stock_options_Price_In_Canadia
Stock options (Price In Canadian Dollars) (Details) | 12 Months Ended |
In Thousands, unless otherwise specified | Dec. 31, 2013 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Weighted average remaining life (years) | '5 years 8 months 23 days |
Price In Canadian Dollars 0.54 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and exercisable | 88 |
Weighted average remaining life (years) | '4 years 3 months 4 days |
Price In Canadian Dollars 0.63 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and exercisable | 303 |
Weighted average remaining life (years) | '4 years 2 months 16 days |
Price In Canadian Dollars 0.81 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and exercisable | 3,702 |
Weighted average remaining life (years) | '3 years 11 months 19 days |
Currency Canadian Dollar [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and exercisable | 4,093 |
Weighted average remaining life (years) | '3 years 11 months 26 days |
Stock_Options_Price_In_US_Doll
Stock Options (Price In US Dollars) (Details) | 12 Months Ended |
In Thousands, unless otherwise specified | Dec. 31, 2013 |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and Exercisable | 1,631 |
Remaining life (years) | '5 years 8 months 23 days |
Price In Us Dollars 0.15 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and Exercisable | 33 |
Remaining life (years) | '5 years 8 months 16 days |
Price In Us Dollars 0.18 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and Exercisable | 61 |
Remaining life (years) | '5 years 5 months 12 days |
Price In Us Dollars 0.20 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and Exercisable | 254 |
Remaining life (years) | '5 years 3 months 29 days |
Price In Us Dollars 0.24 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and Exercisable | 250 |
Remaining life (years) | '6 years 8 months 26 days |
Price In Us Dollars 0.32 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and Exercisable | 31 |
Remaining life (years) | '6 years 8 months 16 days |
Price In Us Dollars 0.35 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and Exercisable | 689 |
Remaining life (years) | '5 years 11 months 19 days |
Price In Us Dollars 0.50 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and Exercisable | 94 |
Remaining life (years) | '4 years 11 months 12 days |
Price In Us Dollars 0.56 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and Exercisable | 100 |
Remaining life (years) | '6 years 18 days |
Price In Us Dollars 0.63 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and Exercisable | 44 |
Remaining life (years) | '4 years 8 months 12 days |
Price In US Dollars 0.80 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and Exercisable | 25 |
Remaining life (years) | '6 years 4 months 6 days |
Price In Us Dollars 0.98 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and Exercisable | 10 |
Remaining life (years) | '6 years 5 months 19 days |
Price In Us Dollars 1.80 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and Exercisable | 4 |
Remaining life (years) | '1 year 8 months 23 days |
Price In Us Dollars 5.04 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and Exercisable | 7 |
Remaining life (years) | '2 months 23 days |
Price In Us Dollars 5.22 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and Exercisable | 2 |
Remaining life (years) | '1 year 5 months 1 day |
Price In Us Dollars 7.20 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and Exercisable | 2 |
Remaining life (years) | '8 months 16 days |
Price In Us Dollars 10.26 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and Exercisable | 12 |
Remaining life (years) | '4 months 17 days |
Price In Us Dollars 11.34 [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Outstanding and Exercisable | 13 |
Remaining life (years) | '1 month 17 days |
Stock_options_Options_Were_Gra
Stock options (Options Were Granted Based On The Black Scholes Option Pricing Model) (Details) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' |
Expected dividend | 0.00% | 0.00% |
Expected life | '7 years | '7 years |
Minimum [Member] | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' |
Risk-free interest rate | 1.10% | 1.09% |
Expected volatility | 144.00% | 118.00% |
Maximum [Member] | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' |
Risk-free interest rate | 1.73% | 1.26% |
Expected volatility | 175.00% | 133.00% |
Stock_options_Additional_Infor
Stock options - Additional Information (Details) (USD $) | 1 Months Ended | 12 Months Ended | |||||
In Thousands, except Per Share data, unless otherwise specified | Jun. 24, 2010 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Jun. 24, 2010 | Jun. 24, 2010 |
General and Administrative Expense [Member] | General and Administrative Expense [Member] | Stock Option [Member] | Stock Option [Member] | Stock Option [Member] | Plan Maximum Amendment [Member] | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Shares issuable under Stock Option Plan | ' | ' | ' | ' | ' | 20,000 | 7,290 |
Percentage Of Total Number Of Share Issued and Outstanding | 25.00% | ' | ' | ' | ' | ' | ' |
Allocated Share-based Compensation Expense | ' | $87 | $326 | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | ' | ' | ' | $0.32 | $0.32 | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | ' | ' | ' | $0 | ' | ' | ' |
Derivative_Liabilities_Gain_Lo
Derivative Liabilities (Gain Loss on Derivative Instruments) (Details) (USD $) | 12 Months Ended | 208 Months Ended | |
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 |
Derivative Instruments, Gain (Loss) [Line Items] | ' | ' | ' |
Gain/(Loss) on Derivative Instruments | $3,777 | ($1,563) | $7,034 |
Warrant expiring April 15, 2015 [Member] | ' | ' | ' |
Derivative Instruments, Gain (Loss) [Line Items] | ' | ' | ' |
Gain/(Loss) on Derivative Instruments | 2,683 | -1,026 | ' |
Warrant expiring March 29, 2016 [Member] | ' | ' | ' |
Derivative Instruments, Gain (Loss) [Line Items] | ' | ' | ' |
Gain/(Loss) on Derivative Instruments | 1,052 | -507 | ' |
Rights Offering Derivative [Member] | ' | ' | ' |
Derivative Instruments, Gain (Loss) [Line Items] | ' | ' | ' |
Gain/(Loss) on Derivative Instruments | 0 | 0 | ' |
Options to Contractors [Member] | ' | ' | ' |
Derivative Instruments, Gain (Loss) [Line Items] | ' | ' | ' |
Gain/(Loss) on Derivative Instruments | $42 | ($30) | ' |
Derivative_Liabilities_Additio
Derivative Liabilities - Additional Information (Details) | 12 Months Ended | 208 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | |||||||||||||||
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | ||||
USD ($) | USD ($) | USD ($) | Options Held [Member] | Options Held [Member] | Investor warrants expiring April 30, 2015 [Member] | Investor warrants expiring April 30, 2015 [Member] | Investor warrants expiring April 30, 2015 [Member] | Investor warrants expiring March 29, 2016 [Member] | Investor warrants expiring March 29, 2016 [Member] | Investor warrants expiring March 29, 2016 [Member] | Rights Offering Derivative [Member] | Rights Offering Derivative [Member] | Options to Contractors [Member] | Options to Contractors [Member] | Options to Contractors [Member] | |||||
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |||||||||||
Derivative [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
Common shares issuable upon exercise of outstanding warrants | 22,035 | ' | 22,035 | ' | ' | 13,337 | [1] | ' | ' | 4,698 | [2] | ' | ' | ' | ' | ' | ' | ' | ||
Warrant exercise price | ' | ' | ' | ' | ' | ' | ' | 1.44 | [1] | ' | ' | 1.44 | [2] | ' | ' | ' | ' | ' | ||
Expiration Date | ' | ' | ' | ' | ' | 30-Apr-15 | [1] | ' | ' | 29-Mar-16 | [2] | ' | ' | ' | ' | ' | ' | ' | ||
Fair value of warrants | ' | ' | ' | ' | ' | $2,015 | $4,698 | ' | $794 | $1,847 | ' | ' | ' | ' | ' | ' | ||||
Gain/(Loss) on Derivative Instruments | 3,777 | -1,563 | 7,034 | ' | ' | 2,683 | -1,026 | ' | 1,052 | -507 | ' | 0 | 0 | 42 | -30 | ' | ||||
Rights offered for each common shares held | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 108 | ||||
Derivative Liability | ' | ' | ' | $54 | $96 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||
[1] | On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement (bPrivate Placementb) of 240,066 units, at a price of $0.03 CAD per unit for net proceeds of CAD$7,200. Each unit consisted of one common share and one common share purchase warrant (a bWarrantb). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date. | |||||||||||||||||||
[2] | On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of $0.03 CAD per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a bWarrantb). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date. |
Fair_Value_Measurements_Assets
Fair Value Measurements (Assets/Liabilities Measured at Fair Value on Recurring Basis) (Details) (Fair Value, Measurements, Recurring, USD $) | Dec. 31, 2013 |
In Thousands, unless otherwise specified | |
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ' |
Cash equivalents | $1,663 |
Derivative liabilities | 2,863 |
Quoted Price in Active Markets for Identical Instruments Level 1 [Member] | ' |
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ' |
Cash equivalents | 0 |
Derivative liabilities | 0 |
Significant Other Observable Inputs Level 2 [Member] | ' |
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ' |
Cash equivalents | 1,663 |
Derivative liabilities | 2,863 |
Significant Unobservable Inputs Level 3 [Member] | ' |
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items] | ' |
Cash equivalents | 0 |
Derivative liabilities | $0 |
Fair_Value_Measurements_Additi
Fair Value Measurements - Additional Information (Details) | 12 Months Ended |
Dec. 31, 2013 | |
Warrant [Member] | ' |
Assumptions used to Determine Fair Value Options [Line Items] | ' |
Expected dividend rate | 0.00% |
Warrant [Member] | Minimum [Member] | ' |
Assumptions used to Determine Fair Value Options [Line Items] | ' |
Risk free interest rate | 1.10% |
Expected volatility rate | 144.00% |
Expected life | '1 year 3 months 18 days |
Warrant [Member] | Maximum [Member] | ' |
Assumptions used to Determine Fair Value Options [Line Items] | ' |
Risk free interest rate | 1.73% |
Expected volatility rate | 175.00% |
Expected life | '2 years 2 months 12 days |
Employee Stock Option [Member] | ' |
Assumptions used to Determine Fair Value Options [Line Items] | ' |
Expected dividend rate | 0.00% |
Employee Stock Option [Member] | Minimum [Member] | ' |
Assumptions used to Determine Fair Value Options [Line Items] | ' |
Risk free interest rate | 1.43% |
Expected volatility rate | 154.00% |
Expected life | '3 years 10 months 24 days |
Employee Stock Option [Member] | Maximum [Member] | ' |
Assumptions used to Determine Fair Value Options [Line Items] | ' |
Risk free interest rate | 1.46% |
Expected volatility rate | 172.00% |
Expected life | '4 years 4 months 24 days |
Shareholders_Equity_Warrants_O
Shareholders' Equity (Warrants Outstanding to Purchase Common Stock) (Details) | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | ||
In Thousands, unless otherwise specified | Investor warrants expiring April 30, 2015 [Member] | Investor warrants expiring March 29, 2016 [Member] | Investor Warrants expiring Novermber 22, 2020 [Member] | |||
Class of Warrant or Right [Line Items] | ' | ' | ' | ' | ||
Common Shares Issuable Upon Exercise of Outstanding Warrants at December 31, 2013 | 22,035 | 13,337 | [1] | 4,698 | [2] | 4,000 |
Exercise Price CND/USD | ' | 1.44 | [1] | 1.44 | [2] | 0.5 |
Expiration Date | ' | 30-Apr-15 | [1] | 29-Mar-16 | [2] | 22-Nov-20 |
[1] | On April 30, 2010, the Company announced that it had completed a first closing of a non-brokered private placement (bPrivate Placementb) of 240,066 units, at a price of $0.03 CAD per unit for net proceeds of CAD$7,200. Each unit consisted of one common share and one common share purchase warrant (a bWarrantb). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date. | |||||
[2] | On March 29, 2011, the Company announced that it had completed a non-brokered rights offering of 84,559 units, at a price of $0.03 CAD per unit for total net proceeds of $2,547. Each unit consisted of one common share and one common share purchase warrant (a bWarrantb). As a result of the Share Consolidation, each eighteen (18) Warrants now entitle the holder thereof to purchase one common share of the Company at a purchase price of CAD$1.44 per whole share for a period of five years from the issue date. |
Shareholders_Equity_Warrants_O1
Shareholders' Equity (Warrants Outstanding to Purchase Common Stock) (Parenthetical) (Details) | Dec. 31, 2013 | Apr. 30, 2010 | Mar. 29, 2011 | Mar. 29, 2011 |
In Thousands, except Per Share data, unless otherwise specified | Private Placement [Member] | Non-Broker Rights Offering [Member] | Non-Broker Rights Offering [Member] | |
CAD | USD ($) | CAD | ||
Class of Warrant or Right [Line Items] | ' | ' | ' | ' |
Issuance of stock, price per share | ' | 0.03 | ' | 0.03 |
Proceeds from issuance of unit | ' | 7,200 | $2,547 | ' |
Common shares issuable upon exercise of outstanding warrants | 22,035 | 18 | 18 | 18 |
Warrants, exercise Price | ' | 1.44 | 1.44 | 1.44 |
Stock Issued During Period, Shares, New Issues | ' | 240,066 | 84,559 | 84,559 |
Shareholders_Equity_Additional
Shareholders' Equity - Additional Information (Details) | 12 Months Ended | 208 Months Ended | 1 Months Ended | ||||
In Thousands, except Per Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Nov. 22, 2013 | Nov. 22, 2013 |
USD ($) | USD ($) | USD ($) | U.S.dollars [Member] | Canadian dollars [Member] | Private Placement [Member] | Gross Proceeds [Member] | |
Equity Financing [Member] | Private Placement [Member] | ||||||
USD ($) | Equity Financing [Member] | ||||||
USD ($) | |||||||
Stockholders Equity Note [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Weighted average exercise price of warrants | ' | ' | ' | 0.5 | 1.44 | ' | ' |
Weighted average remaining life of warrants | ' | ' | ' | '6 years 10 months 24 days | '2 years 7 months 6 days | ' | ' |
Share Price | ' | ' | ' | ' | ' | ' | $4,000 |
Issuance of units, net of issue costs | $1,570 | $0 | $88,013 | ' | ' | ' | $1,600 |
Price Per Units | ' | ' | ' | ' | ' | $0.40 | ' |
Research_and_Development_Inves
Research and Development (Investment Tax Credits Earned) (Details) (USD $) | 12 Months Ended | 208 Months Ended | |
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 |
Research and Development Arrangement, Contract to Perform for Others [Line Items] | ' | ' | ' |
Research and development | $579 | $2,075 | $69,746 |
Investment tax credits | 0 | 0 | -1,632 |
National Research Council grants | 0 | 0 | -197 |
Research and Development Net | $579 | $2,075 | $67,917 |
Commitments_and_Contingencies_1
Commitments and Contingencies (Contractual Obligations and Commitments) (Details) (USD $) | Dec. 31, 2013 |
In Thousands, unless otherwise specified | |
Loss Contingencies [Line Items] | ' |
Less than 1 year | $55 |
1-3 years | 0 |
Total | 55 |
LifeSci Advisors, LLC [Member] | ' |
Loss Contingencies [Line Items] | ' |
Less than 1 year | 55 |
1-3 years | 0 |
Total | $55 |
Commitments_and_Contingencies_2
Commitments and Contingencies - Additional Information (Details) (USD $) | 1 Months Ended |
In Thousands, unless otherwise specified | Feb. 20, 2013 |
Loss Contingencies [Line Items] | ' |
Milestone Payment Fees | $100,000 |
Issue Of Convertible Common Stock As Per Licence Agreement | 13,902 |
Expired Convertible Common Stock | 21,250 |
Licensed Product [Member] | ' |
Loss Contingencies [Line Items] | ' |
Royalty Percent | 2.50% |
Discount On Royalty Percent | 1.00% |
Minimum Amount To Be Bought To Get Discount On Royalty | $150,000 |
Sublicensed Technology [Member] | ' |
Loss Contingencies [Line Items] | ' |
Royalty Percent | 5.00% |
Subsequent_Events_Additional_I
Subsequent Events - Additional Information (Details) (USD $) | 12 Months Ended | 208 Months Ended | 1 Months Ended | ||
In Thousands, except Per Share data, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Mar. 05, 2014 | Jan. 24, 2014 |
Subsequent Event [Member] | Subsequent Event [Member] | ||||
Subsequent Event [Line Items] | ' | ' | ' | ' | ' |
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period | ' | ' | ' | 150,000 | ' |
Proceeds From Stock Options Exercised | $0 | $0 | $51 | $52,500 | ' |
Non Executive Compensation | ' | ' | ' | ' | 1,500 |
Increase Decrease In Non Executive Compensation | ' | ' | ' | ' | $2,000 |
Exercise price per common share | ' | ' | ' | $0.35 | ' |
Income_Taxes_Reconciliation_Of
Income Taxes (Reconciliation Of The Combined Canadian Federal And Provincial Income Tax Rate) (Details) (USD $) | 12 Months Ended | |
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 |
Schedule Of Effective Tax Rate [Line Items] | ' | ' |
Domestic gain | $2,620 | ($4,397) |
Foreign loss | -775 | -766 |
Gain before income taxes | 1,845 | -5,163 |
Expected statutory rate (recovery) | 26.50% | 26.50% |
Expected provision for (recovery of) income tax | 489 | -1,368 |
Permanent differences | -977 | 489 |
Change in valuation allowance | 230 | 2,467 |
Non-refundable investment tax credits | 0 | 0 |
Effect of foreign exchange rate differences | 36 | -245 |
Effect of change in future enacted tax rates | 0 | -1,378 |
Effect of tax rate changes and other | 222 | 36 |
Provision for income taxes | $0 | $0 |
Income_Taxes_Future_Income_Tax
Income Taxes (Future Income Taxes (Recovery)) (Details) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
In Thousands, unless otherwise specified | ||
Income Taxes Future Recovery Disclosure [Line Items] | ' | ' |
Future tax assets gross | $27,170 | $26,940 |
Less: valuation allowance | -27,170 | -26,940 |
Net future tax assets | 0 | 0 |
SR&ED expenditures [Member] | ' | ' |
Income Taxes Future Recovery Disclosure [Line Items] | ' | ' |
Future tax assets gross | 2,195 | 2,195 |
Income Tax Loss Carryforwards [Member] | ' | ' |
Income Taxes Future Recovery Disclosure [Line Items] | ' | ' |
Future tax assets gross | 22,220 | 21,783 |
Non Refundable Investment Tax Credit [Member] | ' | ' |
Income Taxes Future Recovery Disclosure [Line Items] | ' | ' |
Future tax assets gross | 1,719 | 1,719 |
Share Issue Cost [Member] | ' | ' |
Income Taxes Future Recovery Disclosure [Line Items] | ' | ' |
Future tax assets gross | 31 | 25 |
Accrued Expenses [Member] | ' | ' |
Income Taxes Future Recovery Disclosure [Line Items] | ' | ' |
Future tax assets gross | 0 | 0 |
Fixed and Intangible Assets [Member] | ' | ' |
Income Taxes Future Recovery Disclosure [Line Items] | ' | ' |
Future tax assets gross | 1,006 | 970 |
Harmonization Credit [Member] | ' | ' |
Income Taxes Future Recovery Disclosure [Line Items] | ' | ' |
Future tax assets gross | $0 | $248 |
Income_Taxes_Income_Tax_Loss_C
Income Taxes (Income Tax Loss Carry Forwards And Non-Refundable Investment tax Credits) (Details) (USD $) | 12 Months Ended | 208 Months Ended | |
In Thousands, unless otherwise specified | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 |
Income Tax [Line Items] | ' | ' | ' |
Investment tax credits | $0 | $0 | $1,632 |
Federal [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
SR&ED expenditures (no expiry) | 8,283 | ' | ' |
Federal [Member] | Year 2014 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 6,089 | ' | 6,089 |
Federal [Member] | Year 2015 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 11,499 | ' | 11,499 |
Federal [Member] | Year 2021 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 26 | ' | 26 |
Investment tax credits | 55 | ' | ' |
Federal [Member] | Year 2022 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 233 | ' | 233 |
Investment tax credits | 548 | ' | ' |
Federal [Member] | Year 2023 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 133 | ' | 133 |
Investment tax credits | 399 | ' | ' |
Federal [Member] | Year 2024 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 1,536 | ' | 1,536 |
Investment tax credits | 178 | ' | ' |
Federal [Member] | Year 2025 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 4,795 | ' | 4,795 |
Investment tax credits | 199 | ' | ' |
Federal [Member] | Year 2026 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 20,562 | ' | 20,562 |
Investment tax credits | 86 | ' | ' |
Federal [Member] | Year 2027 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 8,340 | ' | 8,340 |
Investment tax credits | 90 | ' | ' |
Federal [Member] | Year 2028 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 10,840 | ' | 10,840 |
Investment tax credits | 50 | ' | ' |
Federal [Member] | Year 2029 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 8,502 | ' | 8,502 |
Federal [Member] | Year 2030 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 2,608 | ' | 2,608 |
Federal [Member] | Year 2031 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 3,377 | ' | 3,377 |
Federal [Member] | Year 2018 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Investment tax credits | 10 | ' | ' |
Federal [Member] | Year 2019 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Investment tax credits | 8 | ' | ' |
Federal [Member] | Year 2020 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Investment tax credits | 96 | ' | ' |
Federal [Member] | Year 2032 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 3,491 | ' | 3,491 |
Federal [Member] | Year 2033 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 1,817 | ' | 1,817 |
Province State [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
SR&ED expenditures (no expiry) | 0 | ' | ' |
Province State [Member] | Year 2014 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 6,089 | ' | 6,089 |
Province State [Member] | Year 2015 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 11,499 | ' | 11,499 |
Province State [Member] | Year 2021 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 0 | ' | 0 |
Province State [Member] | Year 2022 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 0 | ' | 0 |
Province State [Member] | Year 2023 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 0 | ' | 0 |
Province State [Member] | Year 2024 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 1,455 | ' | 1,455 |
Province State [Member] | Year 2025 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 4,768 | ' | 4,768 |
Province State [Member] | Year 2026 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 20,496 | ' | 20,496 |
Province State [Member] | Year 2027 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 8,320 | ' | 8,320 |
Province State [Member] | Year 2028 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 10,823 | ' | 10,823 |
Province State [Member] | Year 2029 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 8,502 | ' | 8,502 |
Province State [Member] | Year 2030 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 2,607 | ' | 2,607 |
Province State [Member] | Year 2031 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 3,377 | ' | 3,377 |
Province State [Member] | Year 2032 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | 3,491 | ' | 3,491 |
Province State [Member] | Year 2033 [Member] | ' | ' | ' |
Income Tax [Line Items] | ' | ' | ' |
Income tax loss carryforwards | $1,817 | ' | $1,817 |
Income_Taxes_Additional_Inform
Income Taxes - Additional Information (Details) | 12 Months Ended |
Dec. 31, 2013 | |
Canadian Statutoy Income Tax [Member] | ' |
Income Taxes Disclosure - Additional Information [Line Items] | ' |
Income Tax Rate | 26.50% |
Federal Income Tax [Member] | ' |
Income Taxes Disclosure - Additional Information [Line Items] | ' |
Income Tax Rate | 15.50% |
Provincial Income Tax [Member] | ' |
Income Taxes Disclosure - Additional Information [Line Items] | ' |
Income Tax Rate | 11.00% |